| 2.82 0.07 (2.55%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.7 |
1-year : | 4.13 |
| Resists | First : | 3.17 |
Second : | 3.53 |
| Pivot price | 3.17 |
|||
| Supports | First : | 2.58 |
Second : | 2.15 |
| MAs | MA(5) : | 2.93 |
MA(20) : | 3.14 |
| MA(100) : | 3.21 |
MA(250) : | 5.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 22.5 |
| RSI | RSI(14): 41.1  |
|||
| 52-week | High : | 11.1 | Low : | 2.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VIGL ] has closed above bottom band by 5.3%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.97 - 2.99 | 2.99 - 3 |
| Low: | 2.54 - 2.56 | 2.56 - 2.58 |
| Close: | 2.78 - 2.82 | 2.82 - 2.86 |
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Thu, 28 Mar 2024
HC Wainwright Weighs in on Vigil Neuroscience, Inc.'s Q1 2024 Earnings (NASDAQ:VIGL) - MarketBeat
Wed, 27 Mar 2024
Vigil Neuroscience's Funding Peril: Navigating Market Turbulence in Equity Capital Raises - TipRanks.com - TipRanks
Tue, 26 Mar 2024
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Yahoo Finance
Wed, 20 Mar 2024
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer - GlobeNewswire
Wed, 07 Feb 2024
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference - Yahoo Finance
Wed, 03 Jan 2024
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 9.3 (%) |
| Held by Institutions | 85.6 (%) |
| Shares Short | 988 (K) |
| Shares Short P.Month | 891 (K) |
| EPS | -2.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -54.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -1.33 |
| PEG Ratio | 0 |
| Price to Book value | 0.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|